Completed PHASE1 INTERVENTIONAL 10-arm NCT00887406

Study of GSK961081 in Healthy Volunteer Subjects

A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetic Profile and Pharmacodynamics of Single and Repeat Inhaled Doses of GSK961081 in Healthy Subjects

Sponsor: GlaxoSmithKline

Conditions Pulmonary Disease, Chronic Obstructive

Interventions GSK961081 100mcg RD GSK961081 100mcg SD GSK961081 15mcg SD GSK961081 200mcg SD GSK961081 300mcg RD GSK961081 300mcg SD GSK961081 3mcg SD GSK961081 50mcg SD Placebo RD Placebo SD

Updated 7 times since 2017 Last updated: Sep 28, 2021 Started: Nov 7, 2005 Primary completion: Oct 4, 2006 Completion: Oct 4, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pulmonary Disease, Chronic Obstructive and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Nov 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Sep 2017 [monthly]

Completed PHASE1

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Theravance Biopharma

Data source: Theravance Biopharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom